Evolus (NASDAQ:EOLS) Releases Earnings Results, Misses Estimates By $0.08 EPS

Evolus (NASDAQ:EOLS) released its quarterly earnings data on Wednesday. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.08), FiscalAI reports. The company had revenue of $84.08 million during the quarter, compared to the consensus estimate of $81.55 million.

Here are the key takeaways from Evolus’ conference call:

• Revenue rose 21% to $84.1 million, with toxin revenue of $75.2 million and injectable hyaluronic acid gel revenue of $8.9 million. Evolus said it gained share across U.S. injectable aesthetics as toxin and filler market conditions improved.
• The company generated $4.7 million of adjusted EBITDA, its third consecutive profitable quarter, while continuing to invest in education, marketing, consumer rewards, and international expansion.
• Evolus raised its 2026 revenue outlook to $330 million-$337 million, increased adjusted gross margin guidance to 67.0%-67.5%, narrowed its non-GAAP operating expense range, and reaffirmed a low- to mid-single-digit adjusted EBITDA margin.
• The company expanded its portfolio and geographic reach through the U.S. Profhilo licensing agreement, the Estyme European launch, and new rights in Canada, Australia, and New Zealand. Profhilo requires a full PMA process with anticipated approval around 2030 and is viewed as having more than $100 million in peak annual revenue potential.
• Evolus ended the quarter with $45.2 million in cash, down from $49.8 million in the first quarter, and plans to stock approximately one year of Jeuveau inventory in the U.S. as a precaution against potential tariffs, although management said negotiated payment terms should prevent additional cash use.

Evolus Trading Up 1.0%

EOLS stock traded up $0.06 during midday trading on Wednesday, reaching $6.18. 1,158,685 shares of the company’s stock traded hands, compared to its average volume of 735,845. Evolus has a 52-week low of $3.86 and a 52-week high of $7.95. The stock has a market cap of $407.01 million, a P/E ratio of -9.22 and a beta of 1.35. The stock’s 50-day moving average is $6.46 and its 200 day moving average is $5.51.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on EOLS. BTIG Research reaffirmed a “buy” rating and set a $13.00 price target on shares of Evolus in a report on Wednesday, June 17th. Weiss Ratings upgraded shares of Evolus from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, June 15th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $16.00.

Evolus News Roundup

Here are the key news stories impacting Evolus this week:

• Positive Sentiment: Strong quarterly growth and improved profitability: Second-quarter revenue rose 21.2% year over year to approximately $84.1 million, ahead of estimates. Gross profit reached $57.2 million, while the operating and net losses narrowed from the prior year. Evolus also delivered its third consecutive quarter of positive adjusted EBITDA. Evolus Reports Strong Second Quarter 2026 Financial Results
• Positive Sentiment: Full-year outlook raised: Evolus issued 2026 revenue guidance of $330 million to $337 million, broadly ahead of the approximately $330.4 million analyst consensus, supporting the company’s growth narrative. Evolus Full-Year 2026 Outlook
• Positive Sentiment: Product momentum and market expansion: Management cited double-digit growth for Jeuveau and accelerating adoption of Evolysse. An expanded Symatese partnership will commercialize the Estyme hyaluronic-acid injectable portfolio in Canada, Australia and New Zealand, adding to Evolus’ international growth opportunities. Evolus Expands Strategic Partnership With Symatese
• Neutral Sentiment: Mixed institutional positioning: Recent filings showed 74 institutional investors adding shares and 76 reducing positions, indicating active but divided professional-investor sentiment.
• Negative Sentiment: Quarterly EPS missed expectations: Adjusted diluted EPS was a loss of $0.12, compared with the consensus loss estimate of $0.04. Operating cash flow was also negative at $3.6 million, and total liabilities increased to $278.9 million. Evolus Q2 2026 Earnings
• Negative Sentiment: Insider selling remains a risk signal: Company insiders reported sales but no purchases over the past six months, potentially tempering enthusiasm around the earnings-driven advance.

Institutional Investors Weigh In On Evolus

A number of hedge funds have recently modified their holdings of the business. Caligan Partners LP grew its holdings in Evolus by 23.8% during the third quarter. Caligan Partners LP now owns 4,138,943 shares of the company’s stock valued at $25,413,000 after purchasing an additional 796,973 shares during the period. Soviero Asset Management LP increased its position in Evolus by 98.5% in the fourth quarter. Soviero Asset Management LP now owns 655,000 shares of the company’s stock worth $4,356,000 after buying an additional 325,000 shares in the last quarter. HRT Financial LP bought a new position in shares of Evolus in the fourth quarter worth about $2,850,000. Rhumbline Advisers raised its stake in shares of Evolus by 2.0% in the second quarter. Rhumbline Advisers now owns 85,093 shares of the company’s stock worth $784,000 after buying an additional 1,657 shares during the period. Finally, Knott David M Jr bought a new position in shares of Evolus during the 4th quarter valued at approximately $661,000. Institutional investors own 90.69% of the company’s stock.

Evolus Company Profile

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.